



Tegsedi in Kuwait

The Kuwait MOH named-patient coordination pathway — indicative 2026

NEUROLOGY · HEREDITARY ATTR AMYLOIDOSIS

The clinical situation

Tegsedi (inotersen) is an FDA-approved antisense oligonucleotide against TTR for hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), dosed 284 mg SC weekly. Manufactured by Akcea / Ionis. REMS-enrolled due to risk of thrombocytopenia and glomerulonephritis; weekly platelet and renal monitoring are required. Refrigerated shipment.

The pathway, 5 steps

- 1 Consultation & genetic confirmation.** Treating neurologist confirms TTR variant and hATTR-PN phenotype; baseline platelets, renal function, and vitamin A documented.
- 2 Treating centre & monitoring plan confirmed.** A Kuwaiti tertiary centre (Kuwait City) issues the prescription and commits to weekly platelet + renal monitoring per REMS.
- 3 Kuwait MOH named-patient application.** Clinical rationale, genetic report, REMS monitoring plan, prescription, and product details are filed with MOH for import clearance.
- 4 US-side sourcing & cold-chain logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner; refrigerated shipment booked to weekly schedule.
- 5 Administration & monitoring.** Weekly SC injection (training-supported self-administration possible); platelets, renal function, and vitamin A monitoring per label.

Indicative economics

Reference US cash-pay range: USD 34,000–42,000 per 4-week supply drug-only. Cold-chain logistics, Kuwait MOH documentation, monitoring labs, and concierge coordination are incremental. Full transparent quote at intake.

Indicative first-dose timing

7–14 days from a complete Kuwait MOH application to first-dose delivery, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Kuwait MOH named-patient package with REMS monitoring confirmation. **Logistics.** Cold-chain, temperature-monitored shipment coordination on a weekly schedule. **Concierge case lead.** Named point of contact for family and physician through the full process. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating neurologist.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Tegsedi × Kuwait first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/tegsedi-kuwait.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team